2 (download XLSX Calcium fluorescence data for all cells and slices with metadata
None of these is objectively better for every patient
More research is needed to better understand the overall risk , if any, to humans You have multiple endocrine neoplasia syndrome type 2 (MEN2), a rare inherited disorder that causes tumors Youve had pancreatitis in the last six months You are allergic to semaglutide or any of its ingredients You are planning to have surgery or other procedures that use anesthesia Stop taking semaglutide and seek immediate medical care if you develop symptoms such as: Trouble breathing or swallowing Swelling of the tongue or lips Severe itching or hives Rapid heartbeat, dizziness, or fainting Thoughts of harming yourself Other important considerations Before starting semaglutide, tell your healthcare provider if you have or have had: Kidney or pancreas problems Type 2 diabetes with a history of diabetic retinopathy Depression, suicidal thoughts, or other mental health concerns You should also let your provider know about any medications you take (including prescriptions, over-the-counter drugs, vitamins, or supplements)
Key Takeaways Mounjaro contains tirzepatide , a dual GIP and GLP-1 receptor agonist, while Wegovy contains semaglutide , a single GLP-1 receptor agonist Mounjaro generally produces stronger results in body composition management compared to Wegovy in head-to-head studies Both medications work by reducing appetite and helping you feel fuller for longer, supporting metabolic health goals UK clinic costs are prohibitive : Mounjaro typically costs 300+ monthly, Wegovy around 250+ monthly through private providers Affordable tirzepatide alternatives exist : Tirzeparo offers the same active ingredient at 169-229 monthly with discreet EU delivery Dosing schedules differ : Mounjaro starts at 2.5mg weekly and increases gradually
Triglycerides dropped 28% in Retatrutide-treated patients
